

Hepatocyte growth factor promotes migration of human myeloma cells

Randi Utne Holt, Unn-Merete Fagerli, Vadim Baykov, Torstein Baade Rø, Håkon Hov, Anders Waage, Anders Sundan, Magne Børset

From the Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (RUH, U-MF, VB, TBR, HH, AW, AS, MB); Faculty of Technology, Sør Trøndelag University College, Trondheim, Norway (RUH); Departments of Oncology (U-MF); Hematology (AW); Immunology and Transfusion Medicine, St.Olavs Hospital, Trondheim, Norway (MB)

Citation: Holt RU, Fagerli U-M, Baykov V, Rø TB, Hov H, Waage A, Sundan A and Børset M Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008 APr; 94(4):xxxx-xxxx. DOI:10.3324/haematol.11867

ABSTRACT

Multiple myeloma is characterized by the accumulation and dissemination of malignant plasma cells in the bone marrow (BM). Cell migration is thought to be important for these events. We studied migration in a Transwell twochamber assay and tested the motogenic effect of various cytokines. In addition to insulin-like growth factor (IGF)-1 and stromal cell-derived growth factor (SDF)-1 α , previously known as chemoattractants for myeloma cells, we identified hepatocyte growth factor (HGF) as a potent attractant for myeloma cells. HGF-mediated migration was dependent on phosphatidylinositol-3-kinase (PI3K), involved the MAPK/Erk signaling cascade and VLA-4 integrins, but did not involve Akt, mTOR or G proteins.

Key words: myeloma, cell migration, HGF, SDF-1.

Citation: Utne Holt R, Fagerli U-M, Baykov V, Baade Rø T, Hov H, Waage A, Sundan A and Børset M Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008 APr; 94(4):xxxx-xxxx. DOI:10.3324/haematol.11867

©2008 Ferrata Storti Foundation. This is an open-access paper.

Design and Methods

Assessment of cell viability

Cells were washed in HBSS (37 °C) and seeded ($3x10^{\circ}$ cells/mL RPMI-medium) in 24-well culture plates (Life Technologies, Inc.) with HGF (150 ng/mL), with or without DMSO (0.2%) or inhibitors. Cells were incubated for 22 hrs. (5% CO₂, 37 °C), washed in PBS with BSA(0.1%) and analyzed by the APOPTEST-FITC-kit from Nexins Research (Kattendijkee, The Netherlands). Percentage of apoptotic and live cells was calculated using a Coulter Epics XL-MCL flow cytometer (Beckton D) with EXPO32 ADC software.

Proliferation assay

Cells were seeded $2x10^4$ cells/well in 200 µL of RPMI medium with HGF (150 ng/mL) in 96-well culture plates (Costar, Corning, NY). Inhibitors were added as indicated for each experiment. After 54 hrs., the cells were pulsed with 0.75 µCi methyl-3H-thymidine (NEN Life Science Products, Boston, MA) per well and harvested 18 hrs. later with a Micromate 96 well harvester, and beta radiation was measured with a Matrix 96 counter (Packard, Meriden, CT, USA).

Supplementary Figure









Figure S2. The efficacy of SH-5, rapamycin and AG490 was proven by their influence on INA-6 cell proliferation when cells were grown in RPMI-medium with HGF (150 ng/mL). SH-5 (10 μ M) fully inhibited proliferation. Rapamycin (5 ng/mL) and AG490 (5 μ M) reduced proliferation by 65% and 85% respectively. Error bars represents ± 1SD of three repeated counts in three independent measurements. The figures show one representative out of three similar experiments.

Figure S3. The effect of inhibiting G protein-coupled receptors was assessed. INA-6 cells were stimulated with or without HGF (150 ng/ml) or SDF-1 α (75 ng/mL) and analyzed by the two-chamber migration method as described in Design and Methods. Pertussis toxin was added to both chambers. The result shown represents one out of four similar experiments, and error bars represent +1 SD of six parallel measurements.